Join
Live feed
·
PRReleasevia Quantisnow
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
QNRX· Quoin Pharmaceuticals Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QNRX (Quoin Pharmaceuticals Ltd.) and more on Quantisnow.